In the present study, our bioinformatics analysis first reveals the existence of a conserved guanine-rich sequence within the Zaire ebolavirus L gene. Using various methods, we show that this sequence tends to fold into G-quadruplex RNA. TMPyP4 treatment evidently inhibits L gene expression at the RNA level. Moreover, the mini-replicon assay demonstrates that TMPyP4 effectively inhibits the artificial Zaire ebolavirus mini-genome and is a more potent inhibitor than ribavirin. Although TMPyP4 treatment reduced the replication of the mutant mini-genome when G-quadruplex formation was abolished in the L gene, its inhibitory effect was significantly alleviated compared with wild-type. Our findings thus provide the first evidence that G-quadruplex RNA is present in a negative-sense RNA virus. Finally, G-quadruplex RNA stabilization may represent a new therapeutic strategy against Ebola virus disease.
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In Brief
Wang et al. describe a small molecule that targets the G-quadruplex RNA structure in a negative-sense RNA virus. G-quadruplex RNA stabilization may represent a new therapeutic strategy against Ebola virus. Team, 2014) . The current outbreak of EVD in West Africa poses a serious worldwide threat to public health (Na et al., 2015) . Many health care workers have been infected while caring for patients (Beeching et al., 2014; Lyon et al., 2014) . However, the mechanism used by this virus to enter host cells and the host's immune response to infection is not yet well understood (Aleksandrowicz et al., 2011; Nanbo et al., 2010) . Standard antiviral therapy is not very effective against EBOV (Oestereich et al., 2014) . Until recently, there has been no approved drug or vaccine to treat or prevent EVD in humans (Oestereich et al., 2014) . Therefore, the development of safe, effective, and affordable therapeutics against EVD is especially important for those patients (Choi et al., 2015; Li et al., 2015a) .
INTRODUCTION

Ebola virus disease (EVD) is caused by infection with Zaire ebolavirus (EBOV) (WHO Ebola Response
Each EBOV virion contains one molecule of linearly singlestranded, negative-sense RNA, approximately 19,000 nucleotides in length (Beniac et al., 2012) . It has been shown that a nucleic acid (NA) molecule may adopt a wide array of secondary structures in different sequence contexts (Cao and Woodson, 1998; Pan and Woodson, 1998) . Given the lack of adequate knowledge on EBOV, the development of antiviral drugs against EBOV is complicated (Johansen et al., 2013; Towner et al., 2005; Warren et al., 2014) , and high-throughput screening is now an efficient approach (Elshabrawy et al., 2014; Johansen et al., 2013; Uebelhoer et al., 2014) . However, when agents are designed to target a specific NA structure, it is not necessarily required to think about the exact function of the target NA fragment (Hurley, 2002) . Hence, an NA structure-guided drug design strategy may greatly facilitate anti-EBOV studies (Guan and Disney, 2012; Howe et al., 2015; Velagapudi et al., 2014) . Strikingly, guanine-rich (G-rich) NA can adopt a tetra-stranded structure known as G quadruplex (G4) (Burge et al., 2006; Parkinson et al., 2002) , which contains stacked planar G quartets (Figure 1A) . G4 RNA has aroused a lot of interest (Biffi et al., 2014; Phan, 2010; Wolfe et al., 2014) , partially because RNA is the downstream product of DNA during gene transcription (Millevoi et al., 2012) . Recently, we first revealed a G4 RNA fragment in the core gene of hepatitis C virus , and this is the first report of G4 RNA in a positive-sense ssRNA virus.
In the current study, the bioinformatics analysis and biophysical experiments demonstrate that a highly conserved G-rich sequence is present in the EBOV L gene and can fold into G4 RNA. More importantly, a typical G4 ligand, TMPyP4 (left structure in Figure S1A ), is able to stabilize this specific structure, and thus leads to repression of the L gene in transiently transfected BSR-T7 cells. The mini-replicon assay indicates that TMPyP4 can represent a better anti-EBOV agent than ribavirin. Based on these findings, ligand-induced G4 stabilization can potentially be a promising strategy for anti-EBOV drug development.
RESULTS
Bioinformatics Analysis of the EBOV Genome
In the present study, the most recently released EBOV mRNAs (162 sequences, GenBank accession numbers in File S1) were retrieved from the NCBI database (http://www.ncbi.nlm.nih. gov). Subsequently, bioinformatics analysis was performed across the whole EBOV genome to identify putative G4-forming sequences (PGS) (Tamura et al., 2013) . As shown in File S2, a highly conserved G-rich segment was identified in the L gene, between positions +2105 and +2129. Next, a graphical representation of the consensus sequence ( Figure 1B ; PGS-L in Table S1) was created through WebLogo software (Crooks et al., 2004) . Almost all of the aligned sequences (161/162) contained four continuous Gs in the first G tract, three continuous Gs in the second G tract, three continuous Gs in the third G tract, and three Gs in the fourth G tract; however, the first guanine and the next two guanines were interrupted by an AA-residue fragment in the fourth G tract (File S2). It is plausible that a G4 structure is formed in this sequence (Mukundan and Phan, 2013) . The analysis of these EBOV mRNAs further reveals a cytosine-rich (C-rich) region, which is located in the C terminus of the nucleoprotein (NP) gene, between positions +1804 and +1827 (File S3). And PGS-NP-C (sequence in Table S1 , Figure S1B ) represents the consensus sequence in this region. This analysis possibly indicates the presence of a G-rich complementary strand (PGS-NP in Table S1 ) in the negative-sense genome of EBOV. The L gene codes the viral RNA-dependent RNA polymerase (RdRp, 240 kDa) and plays the major role in the replication of the viral genome and the production of mRNAs (Volchkov et al., 1999) . And NP gene encodes the largest nucleoprotein of this nonsegmented RNA virus (Watanabe et al., 2006) . These PGS candidates (PGS-L and PGS-NP) are anticipated to form G4 structures under physiological conditions and were therefore chosen as targets for further studies.
Characterization of G4 RNA by 1 H NMR In order to determine whether the suspected PGS sequences were really involved in G4 formation, further studies were performed using chemically synthesized oligomers. In G4 studies, 1 H-NMR is unique because it can provide direct evidence for the formation of such structures (Amrane et al., 2014; Chung et al., 2015; . Hence, it was first performed to justify the selection of true G4-forming sequence. The 1 H NMR spectrum of folded PGS-L demonstrated broad imino peaks within the range of 10.0-11.5 ppm (red spectrum in Figure 2A) , suggesting individual Hoogsteen hydrogen bonds involved in inhomogeneous G4 structures . Moreover, 1 H-NMR analysis of the G4-mutated sequence (PGS-L-Mut in Table S1 ) indicated the absence of imino proton NMR signals within the range of 10.0-11.5 ppm (red spectrum in Figure S2A ). Next, the antisense oligonucleotide (ASO) of this sequence (AS-PGS-L in Table S1 ) was added, and additional peaks appeared at the lower field of 11.5-13.5 ppm (blue spectrum in Figure 2A ), indicating the formation of double-stranded RNA (dsRNA) . Conversely, PGS-NP does not fold into G4 structures, as indicated by the absence of imino proton NMR signals within the range of 10.0-11.5 ppm (red spectrum in Figure S2B ). Without the interference of G4 structures, the hybridization was very efficient between PGS-NP and the ASO AS-PGS-NP, as reflected by more evident signals in the dsRNA region (blue spectrum in Figure S2B ). Based on these results, only PGS-L forms G4 RNA in the presence of K + and was therefore used for further studies.
Demonstration of Unimolecular G4 RNA by Gel Electrophoresis NA moves at quite different rates in the electrical field, depending on the individual secondary structure (Wanrooij et al., 2010) . Because G4 RNA is more compact than its single-stranded counterpart, it migrates significantly faster (Wanrooij et al., 2012) . PGS-L was labeled with a fluorescein moiety at its 5 0 terminal and analyzed using native PAGE. To provide accurate sizing information, a fluorescein-labeled G4-mutant sequence (PGS-LMut-FAM in Table S1 ) was run under the same conditions. As shown in Figure 2B , PGS-L-FAM migrates significantly faster than its G4-mutant counterpart, indicating the formation of a compact G4 structure in the presence of K + . Conversely, PGS-
LMut-FAM appears to migrate more rapidly than PGS-L-FAM in the presence of Li + ( Figure 2C ). This could be explained by the fact that only PGS-LMut-FAM was able to fold into stable hairpins without G4 impetus ( Figure S2C ) (Gruber et al., 2008) . Because these two sequences are all the same sequence except a few mutations, they migrate at approximately similar rates in denaturing gel ( Figure 2D ). Moreover, an RNase T1 protection assay was used to identify the G residues involved in the formation of the G4 structure (Haeusler et al., 2014) . In this study, G residues of PGS-L-HEX were numbered from the first one at the 5 0 end. As shown in Figure 2E , RNA cleavage in the presence of LiCl is much more efficient than that in the presence of KCl with a total of 11 G residues numbered in green. Hence, all these G residues are considered to be involved in the formation of the G4 structure. However, RNA cleavage in the presence of LiCl is slightly more efficient than that in the presence of KCl with the fourth G residue (on the first G tract, numbered in black) and the 11th G residue (on the fourth G tract, numbered in purple). Because there are four continuous G residues on the first G tract, the G4 architecture of PGS-L might be somewhat dynamic in nature. Because the difference in the RNA cleavage between different conditions was observed to be much higher at the first G residue, the fourth G residue is preferably located in a linker region. On the basis of the RNase T1 footprinting results, the 11th G residue on the fourth G tract represents the most accessible one to RNase T1 cutting. Overall, these data indicate that PGS-L G4 might be in dynamic equilibrium between two different conformations, including bulge G4 (Mukundan and Phan, 2013) and vacancy G4 (Li et al., 2015b) (Figure S2D ). The 11th G residue will become more accessible to RNase T1 cutting in the vacancy G4 structure (the right structure in Figure S2D ) and less so in the bulge G4 architecture (the left structure in Figure S2D ).
EBOV L Gene Contains a Parallel G4 RNA To further confirm that PGS-L folds into a G4 structure, a circular dichroism (CD) study was performed in the presence of 100 mM KCl. The resultant CD spectrum (blue line in Figure S3A ) is characteristic of a parallel G4 structure, with a positive peak at 264 nm and a negative peak at 242 nm (Dapic et al., 2003) . Next, we further measured the spectra of this sequence in the presence of 100 mM NaCl or LiCl. Based on our observations (red and black lines in Figure S3A ), the intensity of the maximum peak at 264 nm in the CD spectrum was significantly decreased (Qin et al., 2007) . When the temperature was increased from 5 C to 50 C, only a small variation was observed in the CD spectrum ( Figure S3B ), indicating good stability of this folded structure (100 mM KCl).
Next, AS-PGS-L was added to trap the G4 structure. The resultant CD spectroscopy revealed a significant minimum peak at 210 nm in the presence of 1.5 equiv of AS-PGS-L (Figure S3C ), indicating dsRNA formation (A-form) . Moreover, the peak shifted from 264 nm to 270 nm upon 2.5 equiv AS-PGS-L, further indicating a structural alleviation from G4 .
In addition, a CD melting study was performed to quantitatively determine the stabilities of folded PGS-L (Shalaby et al., 2010) . CD absorbance at 264 nm was measured at increasing temperatures. As shown in Figure S4A , the melting temperature (Tm) of this structure was dependent on K + concentrations. In the presence of 100 mM KCl, the Tm was observed to be 55.9 C ± 0.15 C (blue line in Figure S4A ). Next, the stability of folded PGS-L was investigated in the presence of Li + or Na + . As shown in Figure 3A , K + is much more effective than the other two alkali metal ions in promoting the formation of this defined structure (K + > Na + > Li + ), which is a characteristic of G4 (Kumari et al., 2007) . Furthermore, the concentration-independent melting mode confirmed that the folding process was intramolecular ( Figure S4B ). The fast folding kinetics for PGS-L were demonstrated by a very small hysteresis between the cooling and heating ramps ( Figure S4C ).
TMPyP4 Stabilizes and Binds to EBOV L G4 RNA
The above findings already indicate that the specific G-rich sequence in L gene is prone to fold into G4 RNAs. Because 5,10,15,20-tetrakis(1-methyl-4-pyridinio)porphyrin (TMPyP4) is a well-studied G4 ligand Siddiqui-Jain et al., 2002) , a CD melting study was performed to examine its interaction with folded PGS-L. The result indicates that TMPyP4 binding increases the stability of target G4 RNA, as reflected by the increase in the Tm (DTm = 11.9 C; Figures 3B and S4D). 5,10,15,20-Tetra-(N-methyl-2-pyridyl)porphine (TMPyP2, right structure in Figure S1A ) possesses a similar structure to TMPyP4 but lacks the ability to stabilize G4 structures (Siddiqui-Jain et al., 2002) . In accordance with expectation, TMPyP2 treatment provided an alleviated stabilization on this G4 structure (red line in Figure 3B ). (B-D) PAGE analysis was performed under three different conditions, and three gels were demonstrated together. Lanes 1 and 2, 70 mM KCl; lanes 3 and 4, 70 mM LiCl; lanes 5 and 6, denaturing conditions. Lanes 1, 3, 5, FAM-labeled mutant sequence (PGS-LMut-FAM); lanes 2, 4, 6, FAM-labeled wild-type sequence (PGS-L-FAM). Formation of compact G4 was characterized by the species moving faster than the mutant oligonucleotide in the presence of K + (lanes 1 and 2), while an opposite phenomenon was observed in the presence of Li + (lanes 3 and 4). The mutant oligonucleotide showed very similar migration to the wild-type one under denaturing conditions (lanes 5 and 6).
(E) RNase T1 footprinting was used to identify the G residues involved in the formation of G4 structure.
To further determine TMPyP4's binding ability and selectivity for the target G4 RNA, a competitive fluorescent assay was performed . In this assay, thiazole orange (TO) was preincubated with the folded PGS-L, followed by addition of increasing amounts of different compounds (TMPyP4 or TMPyP2). The displacement of TO from G4 RNA can lead to a loss of fluorescence. It was observed that the fluorescence was decreased by more than 50% through treatment with 0.06 mM TMPyP4 ( Figure S5A ), while a much higher concentration of TMPyP2 (1.30 mM) produced a similar loss of fluorescence ( Figure S5B ). This result was well consistent with the CD melting studies.
TMPyP4 Inhibits RNA Synthesis at the G4 Site Because the secondary structure of viral RNA may restrict its conformation (Gamarnik and Andino, 1998) , we are interested in whether TMPyP4 binding to this G4 motif can lead to the stalling of replication at this site . Picornavirus 3D pol is an RdRp with a primer-dependent mechanism (Arias et al., 2008) , which was used to perform an RNA stop assay . The L gene fragment spanning positions +2105 to +2148 (template L-G4 in Table S1 ) was used as a template, which contains the targeted G4 motif and a vicinal and 3 0 -downstream region. The 5 0 FAM-labeled RNA primer (primer L in Table  S1 ) is complementary to the 3 0 end of this template. Hence, primer L was hybridized and extended along template L-G4. Without G4 ligand treatment, 3D pol can extend the primer across the G4 site on template RNA. On the contrary, if TMPyP4 binds to G4, more extension arrest will be observed at the specific G4 site. As shown in Figure 4 (lanes 4-6), TMPyP4 does not evidently enhance the pause of extension at the G4 site in the absence of K + . However, RNA synthesis pausing was gradually promoted at G4 sites upon treatment with increasing amounts of TMPyP4 in the presence of 5 mM K + (lanes 9-11 in Figure 4 ). As shown in lane 8 of Figure 4 , few stopped products were observed at the G4 site, in the absence of TMPyP4. Importantly, a more evident band at the G4 site was observed in the presence of 0.25 mM TMPyP4 (lane 9 in Figure 4 ). And higher levels of inhibition at the G4 site were observed with the 0.50 and 1.0 mM treatments (lanes 10 and 11 in Figure 4 ). Moreover, TMPyP2 treatment (1.0 mM) did not enhance the pause of templatedirected primer extension at the G4 site in the absence or presence of K + (lanes 7 and 12 in Figure 4 ). On the contrary, when the G4-mutated sequence (template L-G4 mut) was treated with TMPyP4 in the absence or presence of K + , the G4 sitespecific termination event was not observed (lanes 14-17 in Figure 4 ). 
EGFP Repression through G4 RNA Stabilization
It is known that the secondary structure of mRNA can affect the translation process (Endoh et al., 2013) . Subsequently, the 27-base-pair sequence, containing either the wild-type G4 motif or the G4-mutant one, was fused to the N terminus of an EGFP reporter gene (plasmid pEGFP-C1 in Figure 5A ), and a pair of constructs (pEB-G4 and pEB-G4Mut) were prepared . These engineered plasmids were transfected into HEK293 cells in parallel, and a confocal fluorescence microscopy study was performed. Based on the results, TMPyP4 treatment significantly inhibited the expression of EGFP in pEB-G4 compared with the DMSO treatment (left half in Figure 5B ), while a much-alleviated effect on EGFP expression was observed for pEB-G4Mut under the same circumstances (right half in Figure 5B ). As a control, TMPyP2 treatment does not significantly affect the expression of EGFP reporter gene. Next, a quantitative flow cytometry approach was performed to measure the expression levels of EGFP, with or without TMPyP4 treatment . Consistent with the above results, an evident reduction in EGFP expression was observed in pEB-G4-transfected cells following 10 mM TMPyP4 treatment compared with the DMSO control ( Figure 5C ). Importantly, TMPyP4 treatment produced a much-alleviated effect on EGFP expression in cells with pEB-G4Mut. Moreover, TMPyP2 treatment did not significantly inhibit the expression of EGFP in pEB-G4 plasmid. These results together suggest that specific G4 RNA stabilization may correspond to the inhibition of reporter gene.
TMPyP4 Inhibits the EBOV L RNA Level Next, RT-qPCR analysis was used to determine whether TMPyP4 can inhibit the EBOV L RNA level in transfected BSR-T7 cells (Hirashima and Seimiya, 2015) . To evaluate the cytotoxicity of TMPyP4 on BSR-T7 cells, an MTT assay was performed. On the basis of the results, a significant reduction in cell viability was observed with TMPyP4 treatment at concentrations higher than 16 mM ( Figure S6 ). In the current study, the L RNA level was determined relative to the transcription of b-actin in host cells. As shown in Figure 6A , transcription of L gene was gradually reduced through treatment with increasing concentrations of TMPyP4. Treatment of cells with 4.0 mM TMPyP4 resulted in a significant reduction in L RNA. Moreover, TMPyP2 treatment (20 mM) led to a much smaller inhibition of the L RNA level in cells compared with those treated with TMPyP4 (4.0 mM). To further validate the selective targeting of EBOV G4 RNA by TMPyP4, pCAGGS-L-Mut plasmid containing a G4-mutated sequence in the L gene was prepared using overlapping extension PCR (OE-PCR) (Heckman and Pease, 2007) . Further assay indicated that the inhibition level of L RNA by TMPyP4 treatment was significantly dropped in cells harboring pCAGGS-L-Mut compared with those harboring pCAGGS-L (the rightmost column in Figure 6A ). These results therefore enhance the likelihood that a G4-mediated mechanism is involved in the inhibition of L gene expression.
TMPyP4 Inhibits the Replication of the EBOV Mini-Genome
Recently, a non-infectious life cycle modeling system has been developed based on a reverse genetics approach (Towner , 2014; Watt et al., 2014) . This cellbased system relies on a viral mini-genome, which controls the expression of a firefly luciferase (Luc). In conjunction with the Luc quantification, this system enables an accurate and rapid test of antivirals against EBOV at Biosafety Level 2 (BSL-2).
In the current study, the EBOV mini-replicon assay was performed using the same conditions as previously reported (Watt et al., 2014) . The tetracistronic mini-genome (pACYCRluc-VP40-GP-VP24) and four support plasmids (pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, and pCAGGS-L) were co-transfected into BSR-T7 cells stably expressing T7 RNA polymerase. Four hours after transfection, these cells were treated with TMPyP4 at various concentrations for 48 hr. TMPyP2 (4.0 mM) and ribavirin (20 mM) were used as controls. Then cell lysates were prepared and Luc activities were measured. The luminescence data (the left half of Figure 6B ) demonstrated that TMPyP4 effectively inhibited the replication of EBOV mini-genome and was a more potent inhibitor than ribavirin and TMPyP2. Treatment with 4.0 mM TMPyP4 resulted in a significant reduction of Luc activity, while the same concentration of TMPyP2 produced much smaller effects in transfected cells. Moreover, a control assay was performed to evaluate the effect of TMPyP4 on mini-genome replication using the G4-mutated L gene. Although TMPyP4 treatment (4.0 mM) reduced the Luc activity of the mutant system to some extent, its inhibitory effect was significantly alleviated when G4 formation was abolished in the L gene (the right half of Figure 6B ). On the basis of these observations, TMPyP4 may target the L gene and function to inhibit the replication of the EBOV mini-genome.
DISCUSSION
EBOV belongs to the most dangerous and deadly pathogens known to humankind. To date, vaccines and drugs for curing EVD are still under development (Elshabrawy et al., 2014; Johansen et al., 2013) , due to the high risk for people when studying EBOV. It is also difficult to study the genetics of this virus because of its virulent characteristics. Another reason why there has not been much progress in this field is because the pharmaceutical companies cannot make large profits treating poor people in Africa. To the best of our knowledge, ZMapp represents the best treatment available (Choi et al., 2015; Rybicki, 2014) . It is an antibody cocktail developed by a US drug company. It is still an experimental drug and has not yet undergone human clinical trials. Favipiravir, an antiviral drug, has been found to be effective in mouse models of EVD (Furuta et al., 2013) , and is still a candidate for clinical trials in humans (Oestereich et al., 2014) . Hence, the need for development of efficient and new anti-EBOV drugs is urgent.
Depending on the sequences, NAs can adopt various secondary structures distinct from the Watson-Crick double helix (Chinen et al., 2015; Salgado et al., 2015) . Recently, G4 DNAs have been visualized in the nuclei of mammalian cells (Biffi et al., 2013) , and many proto-oncogenes have been shown to harbor G4 DNA structures in their promoter regions (Cogoi and Xodo, 2006; Hsu et al., 2009; You et al., 2015) . Genome-wide analysis based on the G4 folding rule have identified many more PGS in the human genome (Huppert and Balasubramanian, 2005) , although not all of these probably form in vivo. Interestingly, a number of ligands, both small molecules and proteins, have been developed that can induce or stabilize G4 DNA (Muller et al., 2010; Takahama et al., 2015; Tosoni et al., 2015) . And drug development based on probing and manipulating G4 DNA structures represents a promising approach in the battle against pathogens and cancer (Bidzinska et al., 2013; Wu and Brosh, 2010) .
In contrast to G4 DNAs, much less attention has been given to G4 RNAs and possible biological functions. G4 RNA structures are more stable than their corresponding DNA counterparts because of the 2 0 -hydroxyl group (Bugaut and Balasubramanian, 2012) . More importantly, substantive evidence for G4 RNA formation in the human transcriptome has been demonstrated in previous studies (Biffi et al., 2014; Kwok and Balasubramanian, 2015) . It has been proved that the G4 RNA motif causes alteration of gene expression on a genome-wide scale in cancer cells (Hirashima and Seimiya, 2015) . In a recent study, a small molecule was used to decrease the synthesis of Epstein-Barr virusencoded nuclear antigen 1 (EBNA1) through G4 RNA stabilization . Hence, if we could identify conserved G-rich sequences with the potential to form G4 RNA structures in EBOV genomes, then it may represent a promising target for anti-EBOV studies.
EBOV carries a negative-sense RNA genome, which is used as a template for mRNA synthesis. To the best of our knowledge, the presence of G4 RNA has not been reported in any negative-sense RNA virus (Harris and Merrick, 2015) . In the present study, we first retrieved the most recently released genomes of EBOV from the NCBI database. The bioinformatics analysis of these sequences reveals a candidate PGS in the L gene of the viral mRNA and another one in the NP gene of the negativesense genomic RNA. Subsequently, 1 H-NMR was employed to evaluate their ability to form G4 RNA. The results revealed that only the candidate PGS (PGS-L) in the L gene was able to fold into G4 RNA. The EBOV genome contains seven genes and the L gene is the only member coding for a non-structural protein. EBOV L protein has been characterized as an RdRp (Volchkov et al., 1999) , which functions to transcribe the genomic (À) ssRNA to complementary (+)ssRNA. This is then used as a template for the expression of individual viral proteins and also for the synthesis of new genomic (À)ssRNA. Hence, we were encouraged to decrease L gene expression through specific G4 stabilization and further inhibit the replication of the whole viral genome.
Hence, a group of biophysical techniques, including gel electrophoresis, CD study, and fluorescence assay, was used to examine G4-forming potential of PGS-L and its interaction with TMPyP4 in the presence of physiological concentrations of K + . Based on our results, this target sequence tends to form G4 RNA, which is further stabilized through binding to TMPyP4. The following RNA stop assay revealed that RNA-directed RNA synthesis was specifically inhibited at the G4 site through TMPyP4 treatment. The specificity of this assay was demonstrated by the absence of pausing with a template that contained a G4-mutant sequence. Hence, quite a significant correlation was established between TMPyP4 and the G4 target in EBOV L gene.
It has been shown that G4 RNA in an open reading frame suppresses translation of the mRNA into protein (Endoh et al., 2013 ). In the current study, we fused the wild-type or G4-mutant sequence to the N terminus of an EGFP reporter gene to test whether TMPyP4 functions as a specific inhibitor. Based on confocal microscopy, TMPyP4 treatment evidently repressed the expression of EGFP in the construct containing the wildtype G4 sequence, while the G4-mutant plasmid was relatively insensitive to this molecule. A flow cytometry assay suggests that the mutation of the G4-forming motif in pEB-G4 impairs repression of EGFP ($6-fold reduced) with TMPyP4 treatment. RT-qPCR showed that transcription of the L gene was specifically inhibited through treatment with TMPyP4 compared with TMPyP2. The mini-replicon assay demonstrated that TMPyP4 effectively inhibited intracellular replication of the EBOV minigenome (Uebelhoer et al., 2014; Watt et al., 2014) . Moreover, TMPyP2 treatment (20 mM) exhibited a much smaller inhibitory effect on mini-genome replication of transfected BSR-T7 cells by comparison with that by TMPyP4 treatment (4.0 mM). Although treatment with 4.0 mM TMPyP4 reduced the replication of the mutant mini-genome when G-quadruplex formation was abolished in the L gene, its inhibitory effect was significantly alleviated compared with wild-type. Specifically, relative mini-genome expression levels by 4.0 mM TMPyP4 dropped by about 9.6-fold in cells harboring the wild-type system (1.69%, 804/47,607) compared with those harboring the mutant one (16.20%, 3,877/23,938) . Such a significant difference between these two mini-genomes therefore enhances the likelihood that a G4-mediated inhibitory mechanism is involved in this process.
Taken together, the current study provides the first evidence that a conserved G4 RNA fragment is present in the EBOV L gene, and TMPyP4 can inhibit the intracellular replication of an artificial EBOV mini-genome with a better effect than ribavirin. To date, this is the first time that a small molecule has been implicated in targeting the G4 structure in a negative-sense RNA virus. Ultimately, we have demonstrated that G4 RNA in the EBOV L gene can be exploited as a new target for the design and development of anti-EBOV compounds.
SIGNIFICANCE
Zaire ebolavirus causes a serious and often fatal Ebola virus disease in humans, and the current outbreak of this disease in West Africa poses a worldwide threat to public health. To date, vaccines and drugs for curing this disease are still under development. In the present study, our bioinformatics analysis reveals the existence of a conserved guanine-rich sequence within the Zaire ebolavirus L gene. Using various methods, we show that this sequence tends to fold into G-quadruplex RNA. TMPyP4 treatment evidently inhibits L gene expression at the RNA level. Moreover, the mini-replicon assay demonstrates that TMPyP4 effectively inhibits the artificial Zaire ebolavirus mini-genome and is a more potent inhibitor than ribavirin. To the best of our knowledge, this is the first time that a small molecule has been implicated in targeting the G-quadruplex structure in a negative-sense RNA virus. G-quadruplex RNA stabilization may represent a new therapeutic strategy against Ebola virus disease.
EXPERIMENTAL PROCEDURES Bioinformatics Analysis
Multiple sequence alignments were performed using Molecular Evolutionary Genetics Analysis software (MEGA, version 6.0; available at: http://www. megasoftware.net). EBOV sequences were retrieved from the NCBI website (http://www.ncbi.nlm.nih.gov), and graphical representation of the aligned sequences was created using the WebLogo program, version 2.8.2 (http:// weblogo.berkeley.edu/).
Gel Electrophoresis
PAGE analysis was performed in a vertical electrophoretic apparatus (DYCZ-22A; Liuyi Instrument Factory) with a temperature control module (4.0 C). The resolving gel has a high concentration (20%) of acrylamide (19: 1 monomer to bis ratio). A fluorescein-labeled RNA sample was prepared in a buffer (10 mM Tris-HCl [pH 7.0]) containing 70 mM KCl. About 10 ng of RNA were loaded for analysis (300 V, 4 hr). Polyacrylamide gels were imaged on a Pharos FX Molecular imager (Bio-Rad) in fluorescence mode.
RNase T1 Footprinting
The 5 0 -end HEX labeled RNA (PGS-L-HEX in Table S1 ) was folded by heating the samples in the presence of 150 mM salts (LiCl or KCl) in 10 mM Tris-HCl (pH 7.6) and 5.0 mM MgCl 2 at 90 C for 5 min and then slow cooled to 4 C.
The RNA was then digested with 0.20 U of RNase T1 (Thermo Fisher Scientific)
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Please cite this article in press as: Wang et al., Chemical Targeting of a G-Quadruplex RNA in the Ebola Virus L Gene, Cell Chemical Biology (2016 ), http://dx.doi.org/10.1016 /j.chembiol.2016 at 4 C for 30 min. The reaction was terminated by adding an equal volume of stop buffer (7 M urea, 10 mM Tris-HCl, and 0.1 mM EDTA [pH 7.5]). Treated RNA was electrophoresed on a denaturing gel (300 V, 5 hr). Finally, the gels were imaged using the above protocol.
Cell Lines
The BSR-T7 cell line was a kind gift from Prof. Mingzhou Chen, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China (Zhang et al., 2013) . The HEK293 cell line was obtained from the American Type Culture Collection. HEK293 and BSR-T7 cells were cultured in DMEM growth medium containing fetal bovine serum (10%), GlutaMAX (2 mM), 100 U/mL penicillin, and 100 mg/mL streptomycin (Invitrogen) at 37 C in a humidified 5% CO 2 environment.
Preparation of EBOV Support Plasmids and the Multicistronic Mini-Genome
The genes coding for EBOV structural proteins and the EBOV-specific mini-genome are based on the genomic clone GenBank: NC_002549.1. The L gene, 6,639 bp long, is divided into three large fragments: the 1612-bp fragment L1 (+11,581 to +13,192) , the 2447-bp fragment L2 (+13,192 to +15,638) and the 2582-bp fragment L3 (+15,638 to +18,219). For generation of the plasmid pCAGGS-L (pCAGGS-L1 + L2 + L3), each fragment was produced through total gene synthesis (Invitrogen). pCAGGS-L1 was constructed by PCR using template L1 and PCR primers (L1-F and L1-R with flanking sequences in Table S1 ) followed by digestion and ligation into the corresponding KpnI/XhoI sites within pCAGGS (Addgene). To prepare pCAGGS-L1 + L2, fragment L2 was digested and ligated into the corresponding XhoI/SmaI sites within pCAGGS-L1. To prepare pCAGGS-L, fragment L3 was PCR amplified using primers (L3-F and L3-R in Table S1 ), and the purified product was cloned into the corresponding SmaI/NotI sites of pCAGGS-L1 + L2. Other three support plasmids (pCAGGS-NP, pCAGGS-VP35, and pCAGGS-VP30) and the tetracistronic mini-genome (pACYC-Rluc-VP40-GP-VP24) were generated according to the literature (Watt et al., 2014) .
Construction of Plasmid pCAGGS-L-Mut
To construct a target vector containing G4-mutated L gene , pCAGGS-L was used as the starting plasmid. The multiple point mutations at nt 2,106, 2,120, and 2,121 (AGG GGT CAT ATG GGA GGG was changed to AGA GGT CAT ATG GGA GCA), were introduced after amplifying DNA fragments containing the mutations. Point mutations were created through OE-PCR of the region between unique restriction sites (XhoI/SmaI) of pCAGGS-L template DNA, and two primer pairs (forward primer in the upstream region [L up-F] , reverse primer in upstream region [L up-R] ; forward primer in the downstream region [L down-F] , reverse primer in the downstream region [L down-R]) were used. The target fragment was digested with XhoI and SmaI and followed by subcloning into the same restriction sites of the pCAGGS-L vector to generate the plasmid construct pCAGGS-L-Mut, which was further confirmed by sequencing.
EBOV Mini-Replicon Assay
This assay was performed as previously described (Watt et al., 2014) . BSR-T7 cells were seeded into each well of a 12-well plate (Corning) at a density of 1.5 3 10 5 cells per well and incubated overnight at 37 C. Cultured cells were cotransfected with plasmids pCAGGS-NP (62.5 ng), pCAGGS-VP35 (62.5 ng), pCAGGS-VP30 (37.5 ng), pCAGGS-L (500 ng), and pACYC-Rluc-VP40-GP-VP24 (125 ng) using the FuGENE HD transfection reagent at 80% confluency.
To determine the effect of TMPyP4 on the mini-genome replication using the G4-mutated L gene, the EBOV mini-replicon assay was performed using the same conditions except that pCAGGS-L was replaced by pCAGGS-L-Mut. Cell medium was replaced 4 hr after transfection with DMEM (2% fetal bovine serum) containing different amounts of compounds or DMSO. At 48 hr after incubation, the cells were washed once with PBS (pH 7.4) and lysed with 200 mL of 1 3 Rluc Lysis buffer (Renilla Luciferase Assay System; Promega). Then 20 mL of each sample lysate was added to 50 mL of luciferase reagent to each well of a 96-well black flat-bottom polystyrene plate (Greiner). Luminescence of the resultant reaction was determined using a multi-mode microplate reader (Varioskan Flash, Thermo Fisher 
NMR spectroscopy
Standard 1 H NMR spectra were determined at 298 K on a Bruker Avance DRX-800 spectrometer equipped with a cryogenic TCI ATM probe . Water suppression was achieved using the excitation sculpting method. RNA samples were prepared in 10 mM PBS (pH 7.0) containing 100 mM KCl and 10% D 2 O at a final concentration of 0.5 mM. All experiments were carried out using a diffusion time (T D ) of 100 ms, an eddy current recovery time (T E ) of 50 ms and a relaxation delay (T R ) of 2 s.
Fluorescence assay
RNA (0.25 μM) was prepared in 10 mM Tris-HCl buffer (pH 7.4) supplemented with 100 mM KCl. TO at a final concentration of 0.50 μM was added and incubated at 25 °C for 1 h. Subsequently, increasing amount of TMPyP4 or TMPyP2 was added and the mixture was incubated for 3 min before determination of the fluorescence spectrum . The solution was excited at 501 nm and all fluorescent spectra (fluorescence area: 510-680 nm) were determined at 25 o C using a LS55 fluorescence spectrometer (Perkin-Elmer Inc., USA) with a 1-cm path-length cell.
CD Studies
RNA samples were prepared in 10 mM Tris-HCl buffer (pH 7.0) supplemented with different concentrations of monovalent ion (K + , Na + or Li + ). CD experiments were carried out at 25 °C using a Jasco-810 spectropolarimeter (Jasco, Easton, MD, USA) with a quartz cell with a 1.0 mm path length. CD spectra were recorded from 350 to 200 nm with a scanning speed of 50 nm/min (bandwidth = 1.0 nm, response time = 2.0 s). CD spectra were baseline-corrected for the signal contributions due to buffer.
CD Melting Studies
Compounds were dissolved as 10 mM stocks in DMSO. CD-melting experiments were performed on a Jasco-810 spectropolarimeter and a water bath accessory was used to control temperature (heating rate = 0.2 °C /min). The CD ellipticity at 264 nm was measured as a function of temperature. The recorded temperature range was set from 4.0 to 95 °C , and the melting point (Tm) corresponds to the midtransition temperature.
RNA Stop Assay
The assay was performed according to a previously reported protocol . Primer-L (300 nM) and template RNA (600 nM) were annealed in a reaction buffer (50 mM HEPES, 20 mM NaCl, 5.0 mM KCl, 5 mM MgCl 2
